| Literature DB >> 22347369 |
Adam I Perlman1, Ather Ali, Valentine Yanchou Njike, David Hom, Anna Davidi, Susan Gould-Fogerite, Carl Milak, David L Katz.
Abstract
BACKGROUND: In a previous trial of massage for osteoarthritis (OA) of the knee, we demonstrated feasibility, safety and possible efficacy, with benefits that persisted at least 8 weeks beyond treatment termination.Entities:
Mesh:
Year: 2012 PMID: 22347369 PMCID: PMC3275589 DOI: 10.1371/journal.pone.0030248
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Participant Flow Diagram.
30- and 60-Minute Massage Protocols.
| 30 minute protocol (25 minutes of table time) | ||
| Region | Time Allotted | Distribution |
| Lower Limbs | 12–15 min (45–50% of session) | From knee down including lower leg, ankle, and foot. From knee up including hips, pelvis, buttocks & thigh. |
| Upper Body | 8–12 min (36–44% of session) | Lower and upper back. Head/Neck/Chest |
| Discretionary | 2–5 min (6–19% of session) | Therapist to expand treatment to other affected areas; i.e. rib cage, flank, upper limbs, etc. |
*Accounting for time spent in transition including the welcome, transition to the massage room, taking off jewelry, and other preparatory activities.
Demographic Characteristics and Baseline Values.
| Variable | Group 1 (n = 25) | Group 2 (n = 25) | Group 3 (n = 25) | Group 4 (n = 25) | Usual Care (n = 25) |
| Gender | |||||
| Female | 15 (12.0%) | 18 (14.4%) | 19 (15.2%) | 17 (13.6%) | 19 (15.2%) |
| Male | 10 (8.0%) | 7 (5.6%) | 6 (4.8%) | 8 (6.4%) | 6 (4.8%) |
| Race | |||||
| White | 23 (18.4%) | 22 (17.6%) | 19 (15.2%) | 20 (16.0%) | 22 (17.6%) |
| Asian | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.8%) | 0 (0.0%) |
| White/Asian | 0 (0.0%) | 1 (0.8%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| African American | 2 (1.6%) | 2 (1.6%) | 4 (3.2%) | 4 (3.2%) | 2 (1.6%) |
| Hispanic | 0 (0.0%) | 0 (0.0%) | 1 (0.8%) | 0 (0.0%) | 0 (0.0%) |
| Unknown | 0 (0.0%) | 0 (0.0%) | 1 (0.8) | 0 (0.0%) | 1 (0.8%) |
| Age (years) | 69.9±8.6 | 61.9±9.5 | 62.6±10.6 | 63.6±13.0 | 63.6±10.2 |
| Body Mass Index (kg/m2) | 31.0±7.5 | 32.1±6.8 | 31.8±6.7 | 31.3±7.1 | 31.7±6.5 |
| WOMAC (mm) | |||||
| Pain | 52.3±19.9 | 42.4±23.0 | 52.5±16.5 | 44.4±19.3 | 46.3±15.4 |
| Stiffness | 53.4±24.1 | 58.6±21.1 | 58.4±24.7 | 51.2±24.4 | 62.8±18.2 |
| Functionality | 52.9±17.9 | 49.5±19.5 | 49.8±19.7 | 48.3±20.2 | 50.5±17.4 |
| Global | 52.9±18.3 | 50.2±19.4 | 53.6±17.3 | 48.0±19.0 | 53.2±14.8 |
| Pain (VAS) (mm) | 61.2±16.8 | 64.0±12.7 | 66.4±11.3 | 59.2±13.3 | 57.6±9.0 |
| 50-foot walk (seconds) | 18.3±6.9 | 16.8±7.0 | 15.6±3.2 | 15.7±5.4 | 15.7±2.8 |
| Range of Motion (degrees) | 108.7±14.6 | 114.4±10.4 | 115.3±10.5 | 112.8±12.6 | 115.6±9.6 |
Values are mean ± SD except otherwise stated.
Mean change (95% CI) in outcomes at 8-weeks post-baseline (primary endpoint).
| GROUP (n) | Group 1 (n = 22) | Group 2 (n = 24) | Group 3 (n = 24) | Group 4 (n = 25) | Usual Care (n = 24) |
| DOSE | 30 min 1×/wk | 30 min 2×/wk | 60 min 1×/wk | 60 min 2×/wk | (no massage) |
| TOTAL MASSAGE RECEIVED | 240 min | 360 min | 480 min | 720 min | 0 min |
| WOMAC (mm) | |||||
| Pain | −15.1 (−23.4, −6.8) | −14.4 (−23.8, −5.1) | −27.2 (−36.3, −18.0) | −27.7 (−36.9, −18.6) | −5.6 (−13.1, 1.9) |
| Stiffness | −19.0 (−30.4, −7.6) | −23.4 (−34.5, −12.3) | −23.7 (−34.6, −12.7) | −22.3 (−32.9, −11.6) | −6.7 (−15.7, 2.2) |
| Functionality | −18.0 (−25.5, −10.4) | −17.2 (−26.9, −7.6) | −21.2 (−29.3, −13.1) | −22.0 (−31.6, −12.5) | −6.6 (−12.2, −0.9) |
| Global | −17.4 (−25.3, −9.4) | −18.4 (−27.5, −9.2) | −24.0 (−32.1, −15.9) | −24.0 (−32.7, −15.3) | −6.3 (−12.8, 0.1) |
| Visual Analog Scale (mm) | −14.2 (−25.0, −3.4) | −26.1 (−36.8, −15.3) | −39.8 (−48.1, −31.4) | −31.2 (−39.4, −22.9) | −9.8 (−18.6, −1.1) |
| 50-foot walk (seconds) | −1.3 (−3.0, 0.4) | −2.4 (−4.7, −0.1) | −1.7 (−2.7, −0.6) | −2.0 (−3.4, −0.6) | −1.3 (−2.4, −0.2) |
| Range of Motion (degrees) | −2.5 (−7.5, 2.6) | −4.8 (−9.9, 0.4) | −1.3 (−6.2, 3.5) | −6.6 (−11.6, −1.6) | 0.2 (−4.1, 4.4) |
Values are mean with 95% confidence intervals; negative values indicate improvement;
Significant (non-overlap) compared to Usual Care;
Significant (non-overlap) compared to Group 1.
Changes in outcomes at 24-weeks post-baseline.
| GROUP (n) | Group 1 (n = 22) | Group 2 (n = 24) | Group 3 (n = 24) | Group 4 (n = 25) | Usual Care (n = 24) |
| DOSE | 30 min 1×/wk | 30 min 2×/wk | 60 min 1×/wk | 60 min 2×/wk | (no massage) |
| WOMAC (mm) | |||||
| Pain | −12.2 (−22.4, −2.0) | −3.9 (−12.7, 4.9) | −13.7 (−23.4, −4.0) | −14.2 (−24.5, −3.8) | −7.5 (−16.0, 1.1) |
| Stiffness | −15.4 (−26.4, −4.5) | −9.6 (−20.6, 1.3) | −16.9 (−28.5, −5.2) | −16.8 (−29.7, −3.9) | −6.4 (−13.2, 0.4) |
| Functionality | −15.3 (−24.5, −6.1) | −7.4 (−14.8, 0) | −12.1 (−22.0, −2.1) | −14.4 (−23.4, −5.4) | −4.2 (−11.1, 2.7) |
| Global | −14.3 (−22.9, −5.7) | −7.0 (−15.6, 1.6) | −14.2 (−23.4, −5.0) | −15.1 (−25.1, −5.1) | −6.0 (−12.6, 0.5) |
| Visual Analog Scale (mm) | −14.4 (−25.9, −2.8) | −14.0 (−24.7, −3.3) | −18.5 (−29.0, −8.1) | −22.8 (−35.5, −10.1) | −11.5 (−21.0, −2.0) |
| Time to walk 50 Feet (seconds) | −2.4 (−4.4, −0.4) | −1.8 (−3.6, 0) | −1.4 (−2.8, 0) | −1.8 (−3.3, −0.3) | −1.4 (−2.6, −0.2) |
| Range of Motion (degrees) | −4.7±(−10.9, 1.5) | 0.4 (−5.7, 4.8) | −2.7 (−7.6, 2.3) | −8.3 (−14.2, −2.5) | −0.3 (−4.7, 4.1) |
Values are mean with 95% confidence intervals; negative values indicate improvement.
Figure 2Dose-Response Curve.
Dose-response curve plotting dose (total minutes over the course of 8-weeks of massage) (x-axis) vs. improvement (change in WOMAC Global scores after 8-weeks). Dose-response effects plateaued at 480-minutes (Group 3), with no significant improvements noted in the 720-minute (Group 4) dose.
Figure 3Improvement in WOMAC-Global Scores at Assigned Doses of Massage.